James Barry compensation by year
BIO-RAD LABORATORIES Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $536,752 |
| Bonus | $0 |
| Stock awards | $1,214,217 |
| Option awards | $290,493 |
| Non-equity incentive | $266,079 |
| Pension and deferred compensation | $0 |
| All other | $303,685 |
| Total | $2,611,227 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-RAD LABORATORIES, INC. DEF 14A filed March 25, 2026, accession 0000012208-26-000020, and prior-year filings.
How this page was built: the BIO-RAD LABORATORIES, INC. filed document, accession 0000012208-26-000020. Every figure is read from that document and cited to the page and table it appears in. Filed March 25, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 4,110 | $1,245,289 | — |
| RSU | 3,168 | $959,872 | — |
| RSU | 502 | $152,101 | — |
| RSU | 174 | $52,720 | — |
| Option | 885 | — | $343.76 |
| Option | 2,918 | — | $256.45 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-RAD LABORATORIES, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2025 proxy (filed March 25, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-06 | Exercise or conversion derivative | — | 1,056 | $0.00 | 2,112 |
| 2026-09-06 | Exercise or conversion | — | 1,056 | $0.00 | 2,494.68 |
| 2026-09-06 | Tax withholding | — | 470 | $386.11 | 2,024.68 |
| 2026-09-05 | Exercise or conversion | — | 1,027 | $0.00 | 1,807.68 |
| 2026-09-05 | Tax withholding | — | 369 | $386.11 | 1,438.68 |
| 2026-09-05 | Exercise or conversion derivative | — | 1,027 | $0.00 | 3,083 |
| 2026-09-04 | Grant or award derivative | — | 4,313 | $0.00 | 4,313 |
| 2026-09-01 | Tax withholding | — | 154 | $380.96 | 780.68 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments BIO-RAD LABORATORIES discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $540,750 | — | — | $540,750 |
| Change in control and involuntary termination | $754,332 | $2,545,786 | $49,068 | $3,349,186 |
| Change in control, no termination | — | $2,545,786 | — | $2,545,786 |
Per the Potential Payments Upon Termination or Change in Control table in BIO-RAD LABORATORIES, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
BIO-RAD LABORATORIES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Norman Schwartz | Chief Executive Officer and Chairman | $7,995,841 |
| Jonathan DiVincenzo | President and Chief Operating Officer | $3,680,772 |
| Roop Lakkaraju | Executive Vice President, Chief Financial Officer | $2,990,738 |
| Rajat Mehta | Executive Vice President, Global Commercial Operations | $2,680,042 |
| James Barry · this page | Executive Vice President and President, Life Science Group | $2,611,227 |
James Barry's compensation dossier, BIO-RAD LABORATORIES
You have read James Barry's totals and holdings. The dossier adds each equity grant BIO-RAD LABORATORIES disclosed for James Barry and BIO-RAD LABORATORIES's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full BIO-RAD LABORATORIES compensation record
free company briefThis page is one person within BIO-RAD LABORATORIES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIO-RAD LABORATORIES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIO-RAD LABORATORIES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-RAD LABORATORIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.